Kim Wan Jung, Korthals Keith A, Li Suhua, Le Christine, Kalisiak Jarosław, Sharpless K Barry, Fokin Valery V, Miyamoto Yukiko, Eckmann Lars
Department of Medicine, University of California, San Diego, La Jolla, California, USA.
Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02397-16. Print 2017 Jun.
is an important and ubiquitous cause of diarrheal disease. The primary agents in the treatment of giardiasis are nitroheterocyclic drugs, particularly the imidazoles metronidazole and tinidazole and the thiazole nitazoxanide. Although these drugs are generally effective, treatment failures occur in up to 20% of cases, and resistance has been demonstrated and Prior work had suggested that side chain modifications of the imidazole core can lead to new effective 5-nitroimidazole drugs that can combat nitro drug resistance, but the full potential of nitroheterocycles other than imidazole to yield effective new antigiardial agents has not been explored. Here, we generated derivatives of two clinically utilized nitroheterocycles, nitrothiazole and nitrofuran, as well as a third heterocycle, nitropyrrole, which is related to nitroimidazole but has not been systematically investigated as an antimicrobial drug scaffold. Click chemistry was employed to synthesize 442 novel nitroheterocyclic compounds with extensive side chain modifications. Screening of this library against representative strains showed a wide spectrum of activities, with many of the compounds exhibiting superior activity relative to reference drugs and several showing >100-fold increase in potency and the ability to overcome existing forms of metronidazole resistance. The majority of new compounds displayed no cytotoxicity against human cells, and several compounds were orally active against murine giardiasis These findings provide additional impetus for the systematic development of nitroheterocyclic compounds with nonimidazole cores as alternative and improved agents for the treatment of giardiasis and potentially other infectious agents.
是腹泻病的一个重要且普遍存在的病因。贾第虫病治疗的主要药物是硝基杂环药物,特别是咪唑类的甲硝唑和替硝唑以及噻唑类的硝唑尼特。尽管这些药物通常有效,但高达20%的病例会出现治疗失败情况,并且已证实存在耐药性。先前的研究表明,咪唑核心的侧链修饰可产生新的有效5-硝基咪唑药物,能够对抗硝基药物耐药性,但除咪唑外的其他硝基杂环产生有效新型抗贾第虫药物的全部潜力尚未得到探索。在此,我们生成了两种临床使用的硝基杂环(硝基噻唑和硝基呋喃)以及第三种杂环(硝基吡咯,它与硝基咪唑相关,但尚未作为抗菌药物支架进行系统研究)的衍生物。采用点击化学合成了442种具有广泛侧链修饰的新型硝基杂环化合物。针对代表性菌株对该文库进行筛选显示出广泛的活性,许多化合物相对于参考药物表现出优异的活性,有几种化合物的效力提高了100倍以上,并具有克服现有甲硝唑耐药形式的能力。大多数新化合物对人类细胞无细胞毒性,并且有几种化合物对小鼠贾第虫病具有口服活性。这些发现为系统开发具有非咪唑核心的硝基杂环化合物作为治疗贾第虫病及潜在其他感染因子的替代和改进药物提供了额外的动力。